Global mRNA Vaccines and Therapeutics Market to grow at a CAGR of 13% during 2021-26

According to MarkNtel Advisors’ research report, “Global mRNA Vaccines and Therapeutics Market Analysis, 2021,” the market is likely to witness around 13% CAGR during the forecast period, i.e., 2021-26. Application of mRNA vaccines and therapies in cancer treatment and development of COVID-19 vaccine are the prime factors leading to boost the market growth. In addition to this, burgeoning demand for these vaccines and therapeutic medicines for influenza, Ebola, HIV, and other infectious diseases. Further, the increasing number of cancer patients coupled with favorable regulations and standardization of treatment aid the demand for mRNA vaccines and therapeutics, which are more effective and have enhanced immunogenicity, thereby accelerating the overall market growth. 

Key Questions Answered in the Study

1. What are the current and future trends in the global mRNA Vaccines and Therapeutics market? 
2. How has the industry been evolving in terms of geography and services adoption?
3. How has the competition been shaping across the countries, followed by their comparative factorial indexing?
4. What are the key growth drivers and challenges for the Global mRNA Vaccines and Therapeutics market?
5. What are the customer orientation, purchase behavior, and expectations from the Global mRNA Vaccines and Therapeutics market service providers across various regions? 

Immuno-Oncology Accounts for Significant Share of the Global mRNA Vaccines and Therapeutics Market 

Based on the Application Type, the market segments into COVID mRNA and Non-COVID mRNA Applications. The Non-COVID mRNA Application further bifurcates into Immuno-Oncology, Cardiology, Endocrinology, Haematology, and Other Infectious & Rare Diseases. Of these, Immuno-Oncology is more likely to attain a significant share of 65% in the forecast period. This treatment involves exploiting the body’s immune system to identify and distinguish cancerous cells from normal healthy cells, thereby selectively destroying them. Therefore, the rising number of cancer patients coupled with the effectiveness of this treatment fuel the segment growth in the market.

“Global mRNA Vaccines and Therapeutics Market Analysis, 2021” provides comprehensive, qualitative, and quantitative insights on the market potential, key factors impacting the market growth, hotspots, and opportunities available for mRNA Vaccines and Therapeutics providers across the globe. Moreover, the report also encompasses the key strategic imperatives for competitors' success and strategic factorial indexing to measure their capabilities on 16 parameters, which will help companies formulate 'Go to Market' strategies and identify the blue ocean for their offerings.

Europe Region to Witness Significant Growth in the Global mRNA Vaccines and Therapeutics Market During 2021-26

Europe is very likely to register the fastest growth in the Global mRNA Vaccines and Therapeutics Market during 2021-26 due to the prime bio manufacturing juggernauts present in the region. Additionally, the burgeoning number of COVID-19 cases and increasing focus on R&D activities to develop COVID-19 vaccines are other critical factors boosting the market growth, reveals MarkNtel Advisors in their research report, “Global mRNA Vaccines and Therapeutics Market Analysis, 2021.”

According to MarkNtel Advisors, the major leading players in the Global mRNA Vaccines and Therapeutics Market are Arcturus Therapeutics Holdings Inc., BioNTech, CureVac N.V., ethris GmbH, Gennova Biopharmaceuticals Ltd, GlaxoSmithKline plc, Moderna, Pantherna Therapeutics GmbH, Pfizer, Providence Therapeutics, Providence Therapeutics, Silence Therapeutics, and Verve Therapeutics, Inc.

Market Segmentation:

1. By mRNA Type (Nucleoside-Modified mRNA (modRNA), Unmodified mRNA, Self-Amplifying mRNA)
2. By Application Type (COVID mRNA Application [Commercialised Vaccine {mRNA-1273, BNT162b2}, Pipeline Vaccines {CVnCoV, LUNAR-COV19, MRT5500, DS-5670}] Non-COVID mRNA Application [Immuno-Oncology, Cardiology, Endocrinology, Haematology, Other infectious & rare diseases])
3. By End-User (Hospitals & healthcare Clinics, Research Organisation & Institutions, Others)
4. By Region (North America, South America, Europe, Asia-Pacific, Middle East & Africa)
5. By Country (U.S, Canada, Brazil, Argentina, Mexico, Germany, France, The U.K, Spain, Italy, China, India, Japan, Australia, South Korea, Saudi Arabia, UAE, South Africa)
6. By Competitors (Arcturus Therapeutics Holdings Inc., BioNTech, CureVac N.V., ethris GmbH, Gennova Biopharmaceuticals Ltd, GlaxoSmithKline plc, Moderna, Pantherna Therapeutics GmbH, Pfizer, Providence Therapeutics, Providence Therapeutics, Silence Therapeutics, Translate Bio, Versameb AG, Verve Therapeutics, Inc.)